Novartis agrees to acquire Avidity Biosciences for $12 billion Oct 26, 2025 01:00PM
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Oct 26, 2025 01:00PM
Avidity Biosciences (RNA) Reports Positive AOC 1001 Long-term Data Mar 4, 2024 07:04AM
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agr Mar 4, 2024 07:00AM
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Oct 23, 2023 04:05PM
View Older Stories

Oct 7, 2023 07:30AM Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic D
Sep 26, 2023 09:00AM Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society
Sep 25, 2023 09:00AM Avidity Biosciences to Participate in Upcoming Investor Conferences
Sep 21, 2023 04:05PM Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 7, 2023 09:00AM Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs
Aug 31, 2023 09:00AM Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference
Aug 30, 2023 09:00AM Avidity Biosciences to Participate in Upcoming Investor Conferences
Aug 21, 2023 04:05PM Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 15, 2023 09:01AM Avidity Biosciences (RNA) Granted FDA Orphan Drug Designation for AOC 1044
Aug 15, 2023 09:00AM Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
Aug 8, 2023 04:05PM Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights
Jul 21, 2023 04:05PM Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 21, 2023 04:05PM Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 20, 2023 09:00AM Avidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) Day
Jun 8, 2023 09:00AM Avidity Biosciences Announces Upcoming Presentations at the 30th Annual FSHD Society International Research Congress
May 22, 2023 04:05PM Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2023 07:00AM Avidity Biosciences (RNA) Announces FDA Eases Partial Clinical Hold on AOC 1001
May 17, 2023 07:00AM Avidity Biosciences Announces FDA Eases Partial Clinical Hold on AOC 1001 Providing a Clear Path Forward to Finalize Pivotal Dose and Phase 3 Design in Adults with Myotonic Dystrophy Type 1
May 9, 2023 04:05PM Avidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
Apr 27, 2023 03:41PM Avidity Biosciences (RNA) Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA
Apr 27, 2023 03:40PM Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA™ Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in
Apr 24, 2023 09:01AM Avidity Biosciences Inc. (RNA) Granted FDA Fast Track Designation for AOC 1044
Apr 24, 2023 09:00AM Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping
Apr 21, 2023 04:05PM Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 13, 2023 09:00AM Avidity Biosciences to Host Investor and Analyst Event Focused on AOC 1001 Topline Data from Phase 1/2 MARINA™ Trial on April 27, 2023
Mar 30, 2023 07:08AM Avidity Biosciences (RNA) Provides Regulatory Update on AOC 1001
Mar 30, 2023 07:07AM Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA™ Trial at AAN Annual Meeting
Mar 21, 2023 04:05PM Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 13, 2023 09:00AM Avidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference
Mar 1, 2023 04:05PM Avidity Biosciences to Participate in Upcoming Investor Conference
Feb 28, 2023 04:05PM Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights
Feb 28, 2023 09:00AM Avidity Biosciences Honors Rare Disease Day®
Feb 27, 2023 08:00AM Avidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC™ Platform
Feb 23, 2023 08:01AM Avidity Biosciences Inc. (RNA) Appoints Arthur A. Levin to its Board
Feb 23, 2023 08:00AM Avidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader
Feb 21, 2023 08:29PM Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 14, 2023 09:01AM Avidity Biosciences Inc. (RNA) Granted FDA Orphan Drug Designation for AOC 1020
Feb 14, 2023 09:00AM Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
Feb 7, 2023 09:00AM Avidity Biosciences to Participate in Upcoming Investor Conference
Jan 20, 2023 05:12PM Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 18, 2023 09:01AM Avidity Biosciences Inc. (RNA) Granted FDA Fast Track Designation for AOC 1020
Jan 18, 2023 09:00AM Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
Dec 14, 2022 07:09AM Avidity Biosciences Inc. (RNA) Announces Positive AOC 1001 Phase 1/2 MARINA Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle
Dec 14, 2022 07:00AM Avidity Announces Positive AOC 1001 Phase 1/2 MARINA™ Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics
Nov 8, 2022 04:05PM Avidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights
Nov 1, 2022 09:00AM Avidity Biosciences to Participate in Upcoming Investor Conferences
Oct 11, 2022 04:05PM Avidity Biosciences Inc. (RNA) Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044
Oct 11, 2022 04:05PM Avidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping
Oct 6, 2022 09:00AM Avidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annual Congress of World Muscle Society
Sep 29, 2022 09:00AM Avidity Biosciences Announces the Phase 1/2 FORTITUDE™ Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy
View Older Stories